What is Leerink Partnrs’ Estimate for UTHR FY2024 Earnings?
Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects ...
Insmed COO Roger Adsett sells $3.38 million in stock
Roger Adsett, Chief Operating Officer of Insmed Inc. (NASDAQ:INSM), recently sold a substantial amount of company stock. According to an SEC filing, Adsett sold a total of 43,975 shares on February 10 ...
CLYM Stock Touches 52-Week Low at $1.5 Amid Market Challenges
In a challenging market environment, shares of Eliem Therapeutics, Inc. (CLYM) have reached a 52-week low, dipping to $1.5. According to InvestingPro data, the company maintains a strong financial ...
Leerink upgrades CVS Health to Outperform, sees ‘positively skewed’ reward
Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...
Replimune price target raised to $21 from $18 at Leerink
Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...